What is the cost of rare diseases such as Friedreich's Ataxia?
28 Feb 2013
What is the cost of rare diseases such as Friedreich's Ataxia? By analyzing direct and indirect costs of care research in BioMed Central’s open access journal Orphanet Journal of Rare Diseases calculated that conservatively this rare disease costs between £11,000 and £19,000 per person per year. Proper understanding resource allocation is important in minimizing the effect of Friedreich’s Ataxia on people’s lives while maximizing their quality of life.
Diseases are classified as ‘rare’ if they affect less than 1 in 2000 people. Lack of scientific knowledge means that these diseases can be difficult to diagnose and treatment options are limited. Rare Disease Day, February 28th, aims to raise awareness of rare diseases and their impact on people’s lives.
Friedreich’s Ataxia, caused by mutations in the gene encoding the protein frataxin, results in progressive damage to the nervous system. Although rare, it affects one in 50,000 people, and consequently is the most frequent of the inherited ataxias, which all affect a person’s ability to control their muscles. Symptoms usually begin in childhood, and affected people need continual monitoring to assess and assist with developing problems.
Dr Paola Giunti from the UCL Institute of Neurology and UCLH, explained, “The costs of more common progressive diseases such as Parkinson’s Disease are known but it is not really possible to base budget allocations of one disease on the expectations of another without understanding the differences in need.”
People with Friedreich’s Ataxia need specialists, nurses and carers, and there are direct and indirect medical costs, home modifications and loss of earnings to be considered. On the 75 people in the study alone, the UK spent £240,000 on medical care and £300,000 on educational support, respite care, and other support in one year.
Dr Paola Giunti continued, “Our results show that the needs of people with Friedreich’s Ataxia are different, with different costs, to people with Parkinson’s Disease and that a ‘one size fits all’ strategy is unlikely to provide the best care to people with rare diseases.”
- ENDS -
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: +44 (0) 20 3192 2370
Mob: +44 (0) 778 698 1967
1. Impact of Friedreich's Ataxia on health-care resource utilization in the United Kingdom and Germany
Paola Giunti, Julia Greenfield, Alison J Stevenson, Michael H Parkinson, Jodie L Hartmann, Ruediger Sandtmann, James Piercy, Jamie O’Hara, Leo Ruiz Casas and Fiona M Smith
Orphanet Journal of Rare Diseases 2013, 8:38 doi:10.1186/1750-1172-8-38
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central’s open access policy.
Article citation and URL available on request on the day of publication.
2. Orphanet Journal of Rare Diseases is an open access, online journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. @BioMedCentral
4. In recognition of the need to raise awareness of rare diseases, in 2008 a cluster of European countries instigated Rare Disease Day on what is itself a “rare day” – the 29th February. Five years on, Rare Disease Day is an international event marked across the globe, a feat which is testament to the strong desire of patients and their families to raise awareness of these little known and little understood conditions.
This year Rare Disease Day will be marked on the 28th February, the theme is ‘Rare Disorders without Borders.’ The theme highlights the face that advances in rare disease research have more chances of succeeding if sought after internationally when hundreds of teams of researchers from different countries work together to understand the disease and find therapies. This not only makes financial sense but can help spread good practice so that those affected by rare diseases can benefit.